Clinical trials: CD22+ Expression
B ALL, CD22+ Expression
Multi-centric Study
Patients with relapsed/refractory adult acute lymphoblastic leukemia (ALL)have a very dismal prognosis. In this case, allogeneic transplantation is the only curative treatment when patient have obtained a second complete…
- Conditions
- B ALL, CD22+ Expression, Refractory B-ALL
- Trial name
- CHEPRALL (NCT01219816)
- Testing
- Epratuzumab
- Where
- 11 sites in France
- Volunteers
- 57 people
- Sponsor
- Nantes University Hospital